Purpose: drugs are the common point of pharmacovigilance and patient safety programs. Despite 12 using a common language, the same epidemiological method and legislation that requires the 13 operation of the two programs, there does not seem to be a clear relationship between them. 14 Methodology: observational descriptive cross sectional study of the reports database from an 15 institutional patient safety program. Medication errors were classified according to the document 16 The Conceptual Framework for the International Classification for Patient Safety (ICPS) WHO 17 2009. Adverse Reactions (ADR) were classified according to Uppsala Monitoring Center. 18 Results: the omission of drugs or doses was the most frequent error with 42.8% followed by ADRs 19 (20.9%). No harm incidents corresponded to 61.2% and the remaining 38.8% was represented in near 20 missincidents and no harm incidents. There were included 41 ADR and 15 therapeutic failures 21 corresponding to a point-prevalence of 57 ADR/10,000 patients-year and 28.6% (56/196) of reports 22 related to drugs. Phlebitis is the most frequently reported with 23, 7% followed by hypersensitivity 23 reactions with 18.4% and excessive neuromuscular blockade with 13.1%. 24 Conclusions: considering time, level of care and number of bed, ADR prevalence seem low. A very 25 important proportion of reports corresponding to near miss incidents or no harm incidents is not taken 26 into account by the security managers, losing a valuable risk management opportunity in the patient 27 safety programs. 28
Introduction 31
Although by 1848 an attempt had already been made to report adverse drug reaction (ADR)
32
suspicions because of a young woman died by the administration of chloroform during surgery in 33 England (1) , it was only up to 1960 when the first pharmacovigilance (PV) systems were originated 34 as a result of the outbreak of phocomelia caused by the administration of thalidomide (2). After this, 35 a series of articles have been published showing the harm caused by drugs: Talley identified in 1974 36 that 2,9% of admissions to the medical service were for this cause and 6, 2% of these patients died
37
(3). Subsequently, Manasse stated that by 1987 drug mortality affected 12,000 Americans and 38 morbidity reached 15,000 hospitalizations. He also coined the term Drug misadventuring to describe 39 negative drug experiences that he considered a public policy problem derived from the excessive use 40 of drugs and error-prone preparation and distribution systems (4, 5). Lazarou affirm in 1998 that 41 ADR were between the fourth and sixth leading cause of death (6).
42
According to the current definition of the World Health Organization (WHO), PV is "the science and 43 activities relating to the detection, assessment, understanding and prevention of adverse effects or any 44 other possible drug-related problems…". (7). By 2012, the national pharmacovigilance program in 45 Colombia considered that PV should study the problems related with the use of drugs and its effects 46 in society for preventing and resolving them (8, 9) . Today, regulatory agencies work to balance access to drugs with safety concerns, in line with their mission to protect the public health. However, in the 48 first years of the 21st century, the safety of prescribed drugs caught the attention of the public because (14, 15) .
63
PSPs in their philosophy extend the approach of safety in patient care and include in their objectives 64 the inspection of activities related to healthcare, such as skin integrity, prevention of falls, control of 65 medical devices, and surveillance of blood derivatives, among others. These programs incorporate in 66 their concept the inherent risk of health care service and part of their analysis includes the evaluation 67 of the causes of errors or failures in the system that will allow establishing corrective actions in future 68 risk situations for the patient. IBEAS study identified that a 10.5% of the patients presented an 69 adverse event and at least half of these adverse events to drugs could be prevent (16) .
70
Despite these two programs led by the WHO, the negative consequences for the patients' health are 71 still far from being controlled or minimized due, among other reasons, to the current biomedical 72 model that aims to solve health issues with medical interventions, in which drugs are an essential part, 73 and a neoliberal economy that turned health into a business model (17, 18).
74
One of the common points of PVP and PSP are drugs. Despite the use of common language such as 75 ADR, ME and the same epidemiological method (risk approach) added to the fact that in Colombian 76 legislation it is required to have the two programs in order to achieve the certification of institutions 77 for provision of health services to the population, there seems to be no clear articulation between 78 them and it has even been identified that there is a significant variability in PVP, which limits the 79 comparability between different information systems(19). From an institutional PSP, this study characterized the drug related reports sent to the program, identified the differences of their 81 classification.
82
Materials and methods 83 An observational descriptive cross sectional study was carried out with a retrospective collection of 84 information, reports of the institutional PSP application were included during 2015, and there were 85 excluded duplicate reports, invalid (report presenting any inconsistency), tests (information is 86 introduced to verify the integrity of the application), related to the infrastructure of the hospital, and were used, such system/organ affected and seriousness (21).
91
The ethics committee approved the study conforms to the Declaration of Helsinki and resolution 92 008430 of 1993 according to the specified in the article 11 of chapter I. The present study is a risk-93 free investigation therefore written informed consent is not required.
94

Results
95
According to the database used in the study, 1481 safety cases were reported in 2015. After the 96 preliminary analysis, 439 (29.6%) reports were discarded, because they fulfilled some excluded 104 Table 1 shows the distribution of reports according to ICPS, where it can be observed that 42.8%
105
(84/196) correspond to omission of drugs or dose (category 9), followed by 20.9% (41/196) related 106 to ADR (category 11). Sixteen reports could not be classified in any category so it was necessary to 107 create two additional categories: "therapeutic failure" (TF) (category 12) in which 15 reports were 108 identified, and "unclassifiable" (category 20) corresponding to an event of wrong adjustment.
109 During the study period, 9900 patients were attended, which shows an incidence of ADR of 0.56%
127
(456/9900). According to the organ-system affected, the skin and appendages disorders occupy the first place with 42.8% (24/56) followed by the nervous system with 23.2% (13/56). According to the 129 seriousness of ADR, most of them were moderate with 82.2% (46/56) and the remaining 17.8%
130
(10/56) were serious.
131
In the results of the causality analysis with the Naranjo algorithm (68), a score of 7 was obtained in 132 all cases, with the exception of rocuronium, which was assigned an additional point (+8) because of 133 the fact that sugammadex was used to reverse the blockade, however, they all go into the PROBABLE 134 category.
135
Drugs involved in the reports
136
The drugs classification by anatomical group was carried out according to the Anatomical
137
Therapeutical Chemic (ATC) classification (22), in which the group of drugs most frequently 138 involved in the reports were those of the N group with 30.4% (17/56) followed by the group M and 139 C each with 10.7% (6/56). Other groups with low percentage were L and A. It was necessary to create 140 "category X" (without specific drug), which corresponds to the report of an event where a problem is 141 mentioned without specifically describing the international common denomination.
142
Discussion
143
The present study identified that 1 out of 4 reports were rejected, this can be explained by some of 144 the following reasons: incomplete socialization of the program, high healthcare burden, high 145 professionals and students turnover (university hospital). These invalid reports have a negative impact 146 on the program, because the classification of the reports is done manually and increases the reading 147 time.
148
Another finding was a higher frequency of incidents reports related with care (70.8%), followed by 149 those related to drugs (18.8%) and, finally, with medical devices (10.4%). Given that the interest of 150 this work corresponds to drugs, it can be mentioned that the frequency of reports related to this supply is within the numbers identified in studies such as ENEAS (adverse events in hospitals in Spain, with 152 37.4%) (11), IBEAS (adverse events in hospitals in Latin America, with 8.23%) (16) and SYREC
153
(adverse events in Spanish intensive care units, with 24.6%) (23).
154
Regarding the reports classification, it can be affirmed that about half correspond to category 9 of the 155 ICPS (drugs omission) and another important percentage is related to categories 1 and 7 (inadequate 156 conservation conditions and wrong medication). These findings may be a reflection of the lack of a 157 drug distribution system, whose purpose is, precisely, to reduce these errors (24) .
158
A study conducted in the hospitalization service of a clinic in Cali (Colombia) identified that in a 159 period of 20 days the drugs omission was the most common error, although it does not mention which 
167
According to the typology of the reportable events, it is identified that more than half of the reports 168 correspond to harmful incidents. Regarding the harmful incidents, it is necessary to clarify that from 169 the perspective of PSP, these harms are not always related to the affectation of human biology (which 170 in PV would be called ADR), but also include another type of harm that affects other areas of the 171 person or the health system (surgery delay, intensive monitoring, pharmaceutical product damage, 172 etc.). The development and consolidation of the program may lead to the predominance of the near 173 miss incidents report, since they are closer to prevention and constitute the first sign of incidents that 174 may or not lead to harm. This high proportion of harmful incidents reports may be related to the fact 175 that people tend to report those events that cause harm, since those that do not bring consequences can be considered "normal", not worthy of notification or a combination of the "seven capital sins of correspond to ADR and therefore were included in the activities of PVP, while the remaining 180 percentage of incidents that also caused harm were not considered. Additionally, reports of incidents 181 that did not cause harm (no harm incidents, near miss incidents) are not analyzed, mainly due to high 182 workload, which means that an important opportunity to manage the risk is lost, since it should not 183 wait for it to appear ADR to inform and then analyze. This is one of the most relevant findings of the 184 present study, since it demonstrates that PV should also deal with errors or infractions in order to be 185 corrected and prevented. Some authors have identified this need and make a call so that ME are taken 186 into account in PVP (29, 30). It is therefore necessary to visualize these findings as an opportunity 187 for improvement, first identifying that the scope of the two programs pose as a challenge the non-188 duplicity of efforts, and, as an opportunity, not leaving problems unattended, specifically the near 189 miss incidents and no harm incidents.
190
In the referenced studies, it was not possible to identify the results in terms of no harm incidents or 191 near miss-incidents. Some of them describe the results in terms of ADR or ME without taking into 192 account the infractions and other reportable events mentioned at the beginning of the paragraph. It is 193 not possible to make a direct comparison with other studies related to the subject for the following 194 reasons: equal or very similar terms to refer different things (adverse event in PV vs. adverse event 195 in PS); different terms to refer the same (adverse event or preventable ADR in PV vs. ME in PS); 
199
In relation to the PVP and according to the institutional application, a 0.56% prevalence of ADR was 200 estimated during a year, a number that seems low for a fourth-level hospital with 223 hospital beds and 9900 inpatients in the different services during a year, if it is considered that the studies indicate 202 that in this type of hospitals it is presented between 10 to 20% of ADR, of which between a 10 to 203 20% are classified serious and the 0.5 to 0.9%% are mortal (11, 16) . The results of the present study 204 may also be related to underreporting, one of the main problems of passive pharmacovigilance (31). of Bogotá for a year (36), where antibiotics are among the drugs that report the most ADR, although 220 they agree that the skin it is the most affected organ-system. Although some similarities are found in 221 the afore mentioned, differences are also found in some of the results, this can be explained by the 222 type of institution and the methodology used for the identification (passive vs. active).
223
Despite the wide dissemination and published studies related to patient safety, no similar studies were 224 found in the bibliographic review carried out for this study that attempted to reflect on the articulation 225 of PV and PS programs in specific hospitals. However, documents such as the one written by the WHO in 2014 and the EMA in 2015 allow us to deduce that studying the real articulation of these 227 programs is at the heart of the PV and PS programs (29, 37) . For almost 20 years, several authors 228 have discussed the need for a change in the scope, approach or methods used to perform PV. It is 229 possible that these findings are the result of the movement on patient safety or of society's need to 230 counteract the growing outbreak of drug-induced iatrogenic (38-44).
231
There is a need to broaden the vision of health surveillance systems to include aspects such as drug-232 related problems, ME and ADR. It has not yet been possible to integrate and incorporate these terms 233 into a single program, perhaps for reasons that range from the purely philosophical, to a predominance 234 of positivism, passing through political and economic causes whose analysis goes beyond the scope 235 of this research (45) (46) (47) .
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